These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6653641)

  • 1. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of hydralazine.
    Ludden TM; McNay JL; Shepherd AM; Lin MS
    Clin Pharmacokinet; 1982; 7(3):185-205. PubMed ID: 7047041
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism of hydralazine in man. Part II: Investigation of features relevant to drug safety.
    Dubois JP; Schmid K; Riess W; Hanson A; Henningsen NC; Andersson OK
    Arzneimittelforschung; 1987 Feb; 37(2):189-93. PubMed ID: 3580022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydralazine and furosemide kinetics.
    Nomura A; Yasuda H; Katoh K; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1982 Sep; 32(3):303-6. PubMed ID: 7105621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral hydralazine therapy for chronic refractory heart failure.
    Chatterjee K; Parmley WW; Massie B; Greenberg B; Werner J; Klausner S; Norman A
    Circulation; 1976 Dec; 54(6):879-83. PubMed ID: 825327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydralazine kinetics in hypertensive patients after intravenous administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):736-42. PubMed ID: 7438689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of systemic availability of oral hydralazine in heart failure.
    Crawford MH; Ludden TM; Kennedy GT
    Clin Pharmacol Ther; 1985 Nov; 38(5):538-43. PubMed ID: 4053489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.
    Rubin SA; Chatterjee K; Ports TA; Gelberg HJ; Brundage BH; Parmley WW
    Am J Cardiol; 1979 Nov; 44(6):1183-9. PubMed ID: 495513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
    Mulrow JP; Crawford MH
    Clin Pharmacokinet; 1989 Feb; 16(2):86-9. PubMed ID: 2656046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    N Engl J Med; 1982 Jan; 306(2):57-62. PubMed ID: 7053487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure.
    Chirkov YY; De Sciscio M; Sverdlov AL; Leslie S; Sage PR; Horowitz JD
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):131-7. PubMed ID: 20490904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
    Packer M; Gorlin R; Meller J; Medina N
    Clin Pharmacol Ther; 1982 Jul; 32(1):54-61. PubMed ID: 7083730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered prazosin pharmacokinetics in congestive heart failure.
    Baughman RA; Arnold S; Benet LZ; Lin ET; Chatterjee K; Williams RL
    Eur J Clin Pharmacol; 1980 Jun; 17(6):425-8. PubMed ID: 7398734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.